Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Marinus Pharma (MRNS) Misses Q4 EPS by 4c, Revenues Beat
March 9, 2021 7:18 AM ESTMarinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.55), $0.04 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $1.55 million versus the consensus estimate of $1.04 million.
Although 2020 was extremely challenging for so many, we finished the year achieving several important milestones, which has provided momentum into 2021, said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. We remain on track to submit a new... More
